大悅城地產(00207.HK)以14.3億人幣投得南京兩幅地塊
大悅城地產(00207.HK)公佈,附屬重慶澤悅分別以5.2億元及9.1億元人民幣(下同)成功競拍南京市規劃和自然資源局於拍賣會上要約出售No.2022G13地塊及No.2022G14地塊的土地使用權,合計14.3億元,並訂立成交確認書。收購事項相關土地使用權出讓合同預計將於下月9日或之前訂立。
重慶澤悅將於南京成立項目公司,該公司將於收購事項完成後持有2個地塊之權益以進行該等地塊的未來開發。No.2022G13地塊及No.2022G14地塊位於江蘇省南京市浦口區江浦街道豐子河路以北、康健路以東,2個地塊相鄰,集團計劃於該等地塊上開發城鎮住宅。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.